ClinConnect ClinConnect Logo
Search / Trial NCT01105975

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Launched by ELI LILLY AND COMPANY · Apr 15, 2010

Trial Information

Current as of May 29, 2025

Completed

Keywords

Dyslipidemias Mixed Dyslipidemia Hypercholesterolemia Atherosclerosis Atorvastatin Simvastatin Rosuvastatin Metabolic Diseases Antilipemic Agents Enzyme Inhibitors Anticholesteremic Agents Cholesteryl Ester Transfer Protein Inhibitors Cholesteryl Ester Lipid Metabolism Disorders

ClinConnect Summary

Patients will be stratified according to baseline levels of serum triglycerides (\<150 or greater than or equal to 150 milligram/deciliter (mg/dL), HDL-C (\<45 or greater than or equal to 45 mg/dL for men; \<50 or greater than or equal to 50 mg/dL for women), and region (United States or Europe). After a diet lead-in and prior therapy washout phase, subjects meeting all entry criteria will be randomized to one of 10 double-blind treatment groups for a 12 week treatment phase. After randomization, patients will self-administer the study drugs once a day with a low fat meal as their first mea...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Diagnosed with Low High Density Lipoprotein Cholesterol (HDL-C) or hypercholesterolemia, after diet lead-in/washout of lipid therapies
  • Exclusion Criteria:
  • History of coronary heart disease, or hardening of the arteries, or heart does not pump sufficiently well
  • Hypertension or high blood pressure that is not under control or your study physician does not consider the electrical activity of heart (Electrocardiogram \[ECG\]) to be compatible with participation in the study
  • History of a bad skin rash, a prior rash due to a drug or a history of chronic skin disorder (such as psoriasis or eczema)
  • Intolerance to certain lipid modifying drugs (including statins and Cholesteryl Ester Transfer Protein (CETP) inhibitors)
  • Not willing to stop taking prescription or over the counter drugs you use to control fats in your blood (like fish oil, niacin or statin) or pills to decrease your weight, including herbs
  • Not willing to follow the diet (low-fat) that the study physician will recommend
  • Have disease of liver, kidneys, muscles or other organs of body, a serious infection or cancer, or abnormal laboratory tests that study physician does not consider compatible with participation in the study
  • Breastfeeding woman or a woman who can still become pregnant, but are not willing to use a valid birth control measure to prevent pregnancies

About Eli Lilly And Company

Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.

Locations

Dallas, Texas, United States

Houston, Texas, United States

Leipzig, , Germany

Cary, North Carolina, United States

Amsterdam, , Netherlands

Fayetteville, Arkansas, United States

Brandon, Florida, United States

Longwood, Florida, United States

Lexington, Kentucky, United States

Auburn, Maine, United States

Raleigh, North Carolina, United States

Winston Salem, North Carolina, United States

Bristol, Tennessee, United States

Kingsport, Tennessee, United States

Simpsonville, South Carolina, United States

Tacoma, Washington, United States

Vejle, , Denmark

Spring Valley, California, United States

Waterloo, Iowa, United States

Jacksonville, Florida, United States

Edison, New Jersey, United States

Greer, South Carolina, United States

Greensboro, North Carolina, United States

Hickory, North Carolina, United States

Philadelphia, Pennsylvania, United States

Picayune, Mississippi, United States

Salisbury, North Carolina, United States

Warsaw, , Poland

Wroclaw, , Poland

Berlin, , Germany

Indianapolis, Indiana, United States

Wilmington, North Carolina, United States

Wichita, Kansas, United States

San Diego, California, United States

Vista, California, United States

Golden, Colorado, United States

Ponte Vedra, Florida, United States

Baltimore, Maryland, United States

Endwell, New York, United States

Charlotte, North Carolina, United States

Red Lion, Pennsylvania, United States

Yardley, Pennsylvania, United States

Mount Pleasant, South Carolina, United States

Oregon, Wisconsin, United States

Ballerup, , Denmark

Bochum, , Germany

Breda, , Netherlands

Eindhoven, , Netherlands

Geleen, , Netherlands

Groningen, , Netherlands

Leiderdorp, , Netherlands

Rotterdam, , Netherlands

Zoetermeer, , Netherlands

Gdynia, , Poland

Reading, Berkshire, United Kingdom

Chorley, Lancashire, United Kingdom

Liverpool, Merseyside, United Kingdom

Glasgow, Scotland, United Kingdom

Birmingham, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Study Director

Eli Lilly and Company

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials